

PRESS RELEASE



ExonHit receives "Innovative Company" accreditation from the French state innovation agency OSEO

Paris, France, April 6, 2010 - ExonHit Therapeutics (Alternext: ALEHT) today announced that it has obtained the "Innovative Company" accreditation from OSEO (the French state innovation agency), in recognition of the company's cutting-edge innovations in its target sectors. The accreditation means that French innovation-focused mutual funds (FCPI) can now make tax-efficient equity investments in ExonHit Therapeutics for renewable 3-year periods.

"We are delighted to have received this OSEO accreditation, which emphasizes our particularly innovative strategy in genomic profiling that we apply both in therapeutics and in diagnostics. We are continuing our investments and research efforts with a view to offering personalized medical solutions in Alzheimer's disease and cancer - both of which are major public health issues", commented Loïc Maurel MD, President of the Management Board at ExonHit Therapeutics.

This new milestone forms part of ExonHit's unrelenting commitment to innovation in the fields of neurodegenerative diseases and oncology. It follows on from last December's launch of AclarusDx™ the company's first research-use-only molecular test for Alzheimer's disease.

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast-emerging healthcare player active in both therapeutics and diagnostics. The company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative molecular diagnostic tests and therapeutics for neurodegenerative and cancer indications. ExonHit has a balanced investment strategy with in-house development programs and strategic collaborations, in particular with bioMérieux and Allergan).

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The company is listed on Alternext of NYSE Euronext Paris. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Lastly, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

Contacts

ExonHit Therapeutics

Corinne Hoff
+33 1 58 05 47 04
corinne.hoff@exonhit.com

Alize RP

Caroline Carmagnol
+ 33 6 64 18 99 59
caroline@alizerp.com